Study S001070

Oral Semaglutide Pharmacokinetics in Healthy Subjects, Effect of Dosing Schedules

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04513704
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 156
Start: 2020-08-28
Primary completion: 2021-04-20
Lead sponsor: Novo Nordisk A/S
Conditions: Healthy Volunteers Type 2 Diabetes
Interventions: DRUG:Oral Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1243-9641; REGISTRY:2019-004569-42; NIH:2019

Registered primary outcomes

Area under the semaglutide plasma concentration - time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,day10) [From 0 to 24 hours after the 10th dosing (day 10)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0015924	Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects. van Hout M, Clinical pharmacokinetics	2023	Randomized trial	PMID 36932262 DOI	cites ClinicalTrials.gov:NCT04513704; registry reference DERIVED:36932262